Communicable

CMI Communications

Communicable E67: New antifungals & how to use them

NOV 15, 202650 MIN

Description

In this episode of Communicable, hosts Annie Joseph and Josh Nosanchuk welcome Neil Stone and Jeniel Nett to discuss new and emerging antifungal treatments, including ibrexafungerp, rezafungin and olorofim, among others. The panel reviews the evidence behind these drugs, their clinical indications and potential uses, as well as their limitations, including accessibility. The conversation also covers exciting developments in the antifungal pipeline, remaining challenges, and priorities for future research. Further reading WHO fungal priority pathogens list. 2022.  Schwebke JR. Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303). Clin Infect Dis 2022. DOI: 10.1093/cid/ciab750. Thompson GR III, et al. Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial. Clin Infect Dis 2021. DOI: 10.1093/cid/ciaa1380. Thompson GR III, et al. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. Lancet 2023. DOI: 10.1016/S0140-6736(22)02324-8. Donovan FM, et al. Olorofim in Treatment of Patients With Poorly Controlled Disseminated Coccidioidomycosis: A Single-Group, Open-Label, Phase 2b, Multicenter Study. Ann Intern Med 2026. DOI: 10.7326/ANNALS-26-00103.